Fig. S2



Fig. S2. Molecular characterization of the ERBB2IP-mutation reactive T-cell response. (**A**) IFN-γ ELISPOT assay at 20 h. Patient 3737-TIL were co-cultured with DCs transfected with TMG-1 that had been pre-incubated with nothing, or the indicated HLA-blocking antibodies (**left**). As controls for antibody blocking, the HLA-A2 restricted MART-reactive T cell DMF5 (**middle**) and the HLA-DR-restricted tyrosinase-reactive T cell T4 (**right**) were co-cultured with the MART and tyrosinase-positive 624-CIITA melanoma cell line that had been pre-incubated with nothing, or the indicated HLA-blocking antibodies. (**B**) IFN-γ ELISPOT assay at 20 h. Patient 3737-TIL were co-cultured with autologous B cells or allogeneic EBV-B cells partially matched at the

HLA-DQ locus that had been pulsed overnight with DMSO, mutated (mut) ALK or mut ERBB2IP 25-AA long peptides. (C) IFN-γ ELISPOT assay at 20 h. Patient 3737-TIL were co-cultured with autologous B cells that had been pulsed overnight with the mut ERBB2IP 25-AA peptide, or the indicated truncated mut ERBB2IP peptides. All data is representative of 2 independent experiments.